Company Encyclopedia
View More
name
Glycomimetics
GLYC.US
GlycoMimetics, Inc. engages in the discovery and development of therapies for cancers and inflammatory diseases in the United States. The company was founded in 2003 and is based in Monrovia, Maryland.
1.946 T
GLYC.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

    Completed Merger with GlycoMimetics and Previously Announced $200 Million Private Financing Supporting Pipeline of Next Generation Therapeutics for Solid Tumors ...

    GlobeNewswire·
    US
    GLYC
    0.00%
    US
    CBIO
    -3.13%
    GlobeNewswire·
    US
    GLYC
    0.00%
    US
    CBIO
    -3.13%

    GlycoMimetics Inc. Completes 1-for-100 Reverse Stock Split Amid Merger with Crescent Biopharma

    GlycoMimetics Inc. has completed a 1-for-100 reverse stock split as part of its merger with Crescent Biopharma. Each share of Crescent common stock was converted into 0.1445 shares of the new entity. The combined company now has approximately 19.5 million shares outstanding and will trade on Nasdaq under the ticker symbol "CBIO." The new CUSIP number is 38000Q201.

    Reuters·
    US
    CBIO
    -3.13%
    US
    GLYC
    0.00%
    Reuters·
    US
    CBIO
    -3.13%
    US
    GLYC
    0.00%

    Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 Million

    Advancing Lead Program, CR-001, a PD-1 x VEGF Bispecific Antibody, and Developing Pipeline of Novel ADCs as Single Agents and in Combination with CR-001 On Track to Submit IND Application for CR-001 in Fourth Quarter of 2025 with Proof-of-Concept Clinical Data Expected in Second Half of 2026

    Benzinga·
    US
    GLYC
    0.00%
    Benzinga·
    US
    GLYC
    0.00%

    What Does the Market Think About GlycoMimetics?

    GlycoMimetics's GLYC short percent of float has fallen 8.14% since its last report. The company recently reported that it has 1.68 million shares sold short, which is 3.16% of all regular shares that are available for trading.

    Benzinga·
    US
    GLYC
    0.00%
    US
    CBIO
    -3.13%
    Benzinga·
    US
    GLYC
    0.00%
    US
    CBIO
    -3.13%

    12 Health Care Stocks Moving In Thursday's After-Market Session

    In Thursday's after-market session, several health care stocks saw significant movements. Bluejay Diagnostics (BJDX) surged 41.5% to $2.15, with a market cap of $3.2 million. GlycoMimetics (GLYC) rose 30.86% to $0.26, valuing at $16.7 million. Eyenovia (EYEN) increased by 28.97% to $4.05, with a market cap of $11.6 million. Pediatrix Medical Group (MD) gained 8.47% to $15.1, valued at $1.2 billion. Rani Therapeutics (RANI) rose 7.27% to $0.57, and RAPT Therapeutics (RAPT) increased 6.86% to $1.09, with market caps of $19.0 million and $144.1 million, respectively.

    Benzinga·
    US
    MD
    -4.29%
    US
    RANI
    -3.09%
    US
    GLYC
    0.00%
    Benzinga·
    US
    MD
    -4.29%
    US
    RANI
    -3.09%
    US
    GLYC
    0.00%
    © 2025 Longbridge｜Disclaimer